Results of the eValuation of ERTugliflozinEffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)
In this medfyle
Expert Commentary by Mark Cooper, MB, BS, PhD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ADA 2020 - 80th Scientific Sessions and presented by:
Richard E. Pratley, MD
Translational Research Institute, AdventHealth, Orlando, FL, USA
Samuel Dagogo-Jack, MD, DSc
Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN, USA
Christopher P. Cannon, MD
Brigham and Women’s Hospital and Heart and Vascular Center, and Harvard Medical School, Boston, MA, USA
Darren K. McGuire, MD, MHSc
Division of Cardiology, Dept. of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
David Z. Cherney, MD, PhD
Division of Nephrology, Dept. of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada
Mark E. Cooper, MBBS, PhD
Monash University, Melbourne, VIC, Australia
The content is produced by Infomedica, the official reporting partner of ADA 2020 Virtual Meeting. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Dana M. Dabelea, MD, PhD, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Mark Cooper, MB, BS, PhD
Department of Diabetes, Central Clinical School, Monash University
About the Expert
Mark Cooper, MB, BS, PhD
Department of Diabetes, Central Clinical School, Monash University
Mark Cooper is the head of the Department of Diabetes, Monash University. he was previously the the Chief Scientific Officer of the Baker IDI Heart & Diabetes Institute. He is an endocrinologist with an appointment at the Alfred Hospital. He is regularly invited to international meetings and has over 500 peer reviewed publications. Dr Cooper is the 2016 recipient of the Claude Bernard Award from the European Association for the Study of Diabetes. In 2017 he was awarded an Order of Australia (Officer) in part for his research in the field of diabetic complications.
